retatrutide lilly Weight loss drug use requires strict supervision, doctor says Eli Lilly's retatrutide hits Phase

Key findings from the new analysis indicate: Holistic model helps people stick with their treatment: While dropout rates for commercially available GLP-1s can hover around 80% at six months 2 , only 25% of Hims & Hers customers discontinued treatment in that timeframe, highlighting the strength and confidence a holistic, personalized model delivers

[DOI] [PubMed] [Google Scholar] 49.Mehdi SF et al

Previous insulin use and previous glucocorticoid use were identified through redeemed prescriptions (binary variables)

Recent research has suggested that GLP-1 agonists used to treat obesity might be associated with a stroke in the optic nerve, but association is not the same as causation

One of these therapies is reninangiotensinaldosterone system inhibition (RAASi), which has been shown to increase hyperkalemia risk [4]

Parker ED, Lin J, Mahoney T, et al